<DOC>
	<DOCNO>NCT02119819</DOCNO>
	<brief_summary>The main purpose study compare safety effectiveness study drug know LY2944876 exenatide extended-release placebo participant type 2 diabetes mellitus . All drug give injection skin . Participants remain stable dos metformin , prescribed personal investigator metformin study entry . Participants involvement study expect last 30 week .</brief_summary>
	<brief_title>A Study Compare New Drug Type 2 Diabetes Placebo Treatment Already Available Type 2 Diabetes</brief_title>
	<detailed_description>The study include 12 week blind treatment period , neither participant investigator know treatment individual assign . Thereafter follow 12 week period participant investigator know treatment assign . Participants LY2944876 exenatide extended-release continue treatment period , receive placebo follow without treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Men woman diabetes mellitus Type 2 Have screen HbA1c ≥7.0 % ≤10.5 % either diet exercise alone stable dose metformin ( ≥1000 mg/day ) 3 month prior screen Have body mass index ( BMI ) ≥23 ≤45 kilogram per meter square screening Women child bear potential Participants use thiazolidinediones within 3 month prior screen , drug treatment hyperglycemia ( except metformin ) within prior 2 month Participants use insulin diabetic control 6 consecutive day within prior year Participants impair renal function ( serum creatinine &gt; 124 micromole per liter ( µmol/L ) [ 1.4 milligram per deciliter ( mg/dL ) ] woman , &gt; 133 µmol/L [ 1.5 mg/dL ] men )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Weight loss</keyword>
</DOC>